VEGF-A/NRP1 stimulates GIPC1 and Syx complex formation to promote RhoA activation and proliferation in skin cancer cells.
Ayumi Yoshida, Akio Shimizu, Hirotsugu Asano, Tetsuya Kadonosono, Shinae Kizaka Kondoh, Elena Geretti, Akiko Mammoto, Michael Klagsbrun, Misuzu Kurokawa Seo
文献索引:Biol. Open 4 , 1063-76, (2015)
全文:HTML全文
摘要
Neuropilin-1 (NRP1) has been identified as a VEGF-A receptor. DJM-1, a human skin cancer cell line, expresses endogenous VEGF-A and NRP1. In the present study, the RNA interference of VEGF-A or NRP1 suppressed DJM-1 cell proliferation. Furthermore, the overexpression of the NRP1 wild type restored shNRP1-treated DJM-1 cell proliferation, whereas NRP1 cytoplasmic deletion mutants did not. A co-immunoprecipitation analysis revealed that VEGF-A induced interactions between NRP1 and GIPC1, a scaffold protein, and complex formation between GIPC1 and Syx, a RhoGEF. The knockdown of GIPC1 or Syx reduced active RhoA and DJM-1 cell proliferation without affecting the MAPK or Akt pathway. C3 exoenzyme or Y27632 inhibited the VEGF-A-induced proliferation of DJM-1 cells. Conversely, the overexpression of the constitutively active form of RhoA restored the proliferation of siVEGF-A-treated DJM-1 cells. Furthermore, the inhibition of VEGF-A/NRP1 signaling upregulated p27, a CDK inhibitor. A cell-penetrating oligopeptide that targeted GIPC1/Syx complex formation inhibited the VEGF-A-induced activation of RhoA and suppressed DJM-1 cell proliferation. In conclusion, this new signaling pathway of VEGF-A/NRP1 induced cancer cell proliferation by forming a GIPC1/Syx complex that activated RhoA to degrade the p27 protein. © 2015. Published by The Company of Biologists Ltd.
相关化合物
相关文献:
2015-03-15
[Cancer Res. 75(6) , 1102-12, (2015)]
2015-03-01
[Hum. Gene Ther. 26(3) , 172-82, (2015)]
2014-07-01
[Autophagy 10(7) , 1241-55, (2014)]
2015-01-01
[Arch. Toxicol. 89(1) , 107-19, (2015)]
2014-11-01
[Endocrinology 155(11) , 4189-201, (2014)]